vs
Side-by-side financial comparison of Genpact LTD (G) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
Genpact LTD is the larger business by last-quarter revenue ($1.3B vs $619.8M, roughly 2.1× QuidelOrtho Corp). Genpact LTD runs the higher net margin — 11.4% vs -14.8%, a 26.2% gap on every dollar of revenue. On growth, Genpact LTD posted the faster year-over-year revenue change (6.7% vs -10.5%). Over the past eight quarters, Genpact LTD's revenue compounded faster (5.0% CAGR vs -6.6%).
Genpact Ltd. is an American information technology services, consulting, and outsourcing company headquartered in New York City, New York. Founded in Gurgaon, India, and legally domiciled in Bermuda, Genpact employs more than 125,000 people and provides services to clients in over 30 countries worldwide. Genpact is listed on the NYSE and generated revenues of US$4.48 billion in 2023.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
G vs QDEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $619.8M |
| Net Profit | $148.0M | $-91.8M |
| Gross Margin | 36.4% | — |
| Operating Margin | 15.3% | — |
| Net Margin | 11.4% | -14.8% |
| Revenue YoY | 6.7% | -10.5% |
| Net Profit YoY | 13.1% | — |
| EPS (diluted) | $0.86 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $619.8M | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | $699.9M | ||
| Q2 25 | $1.3B | $613.9M | ||
| Q1 25 | $1.2B | $692.8M | ||
| Q4 24 | $1.2B | $707.8M | ||
| Q3 24 | $1.2B | $727.1M | ||
| Q2 24 | $1.2B | $637.0M |
| Q1 26 | $148.0M | $-91.8M | ||
| Q4 25 | $143.1M | — | ||
| Q3 25 | $145.8M | $-733.0M | ||
| Q2 25 | $132.7M | $-255.4M | ||
| Q1 25 | $130.9M | $-12.7M | ||
| Q4 24 | $141.9M | $-178.4M | ||
| Q3 24 | $132.8M | $-19.9M | ||
| Q2 24 | $122.0M | $-147.7M |
| Q1 26 | 36.4% | — | ||
| Q4 25 | 36.6% | — | ||
| Q3 25 | 36.4% | — | ||
| Q2 25 | 35.9% | — | ||
| Q1 25 | 35.3% | — | ||
| Q4 24 | 35.7% | — | ||
| Q3 24 | 35.6% | — | ||
| Q2 24 | 35.4% | — |
| Q1 26 | 15.3% | — | ||
| Q4 25 | 14.8% | — | ||
| Q3 25 | 14.8% | -100.7% | ||
| Q2 25 | 14.3% | -29.4% | ||
| Q1 25 | 15.1% | 4.7% | ||
| Q4 24 | 15.2% | -14.2% | ||
| Q3 24 | 15.0% | 2.1% | ||
| Q2 24 | 14.5% | -18.4% |
| Q1 26 | 11.4% | -14.8% | ||
| Q4 25 | 10.8% | — | ||
| Q3 25 | 11.3% | -104.7% | ||
| Q2 25 | 10.6% | -41.6% | ||
| Q1 25 | 10.8% | -1.8% | ||
| Q4 24 | 11.4% | -25.2% | ||
| Q3 24 | 11.0% | -2.7% | ||
| Q2 24 | 10.4% | -23.2% |
| Q1 26 | $0.86 | $-1.35 | ||
| Q4 25 | $0.82 | — | ||
| Q3 25 | $0.83 | $-10.78 | ||
| Q2 25 | $0.75 | $-3.77 | ||
| Q1 25 | $0.73 | $-0.19 | ||
| Q4 24 | $0.80 | $-2.54 | ||
| Q3 24 | $0.74 | $-0.30 | ||
| Q2 24 | $0.67 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $928.1M | $140.4M |
| Total DebtLower is stronger | $1.5B | $2.5B |
| Stockholders' EquityBook value | $2.5B | $1.9B |
| Total Assets | $5.6B | $5.6B |
| Debt / EquityLower = less leverage | 0.62× | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $928.1M | $140.4M | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $740.8M | $98.1M | ||
| Q2 25 | $663.3M | $151.7M | ||
| Q1 25 | $561.6M | $127.1M | ||
| Q4 24 | $671.6M | $98.3M | ||
| Q3 24 | $1.0B | $143.7M | ||
| Q2 24 | $914.2M | $107.0M |
| Q1 26 | $1.5B | $2.5B | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.2B | $2.5B | ||
| Q2 25 | $1.2B | $2.1B | ||
| Q1 25 | $1.2B | $2.1B | ||
| Q4 24 | $1.2B | $2.1B | ||
| Q3 24 | $1.6B | $2.2B | ||
| Q2 24 | $1.6B | $2.2B |
| Q1 26 | $2.5B | $1.9B | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.5B | $2.0B | ||
| Q2 25 | $2.6B | $2.8B | ||
| Q1 25 | $2.5B | $3.0B | ||
| Q4 24 | $2.4B | $3.0B | ||
| Q3 24 | $2.4B | $3.2B | ||
| Q2 24 | $2.3B | $3.2B |
| Q1 26 | $5.6B | $5.6B | ||
| Q4 25 | $5.8B | — | ||
| Q3 25 | $5.4B | $5.7B | ||
| Q2 25 | $5.3B | $6.4B | ||
| Q1 25 | $4.9B | $6.5B | ||
| Q4 24 | $5.0B | $6.4B | ||
| Q3 24 | $5.3B | $6.8B | ||
| Q2 24 | $5.2B | $6.7B |
| Q1 26 | 0.62× | 1.33× | ||
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.47× | 1.23× | ||
| Q2 25 | 0.47× | 0.74× | ||
| Q1 25 | 0.50× | 0.70× | ||
| Q4 24 | 0.51× | 0.72× | ||
| Q3 24 | 0.68× | 0.68× | ||
| Q2 24 | 0.70× | 0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
G
| Core Business Services | $950.8M | 73% |
| Advanced Technology Solutions | $345.2M | 27% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
